• Gyre Therapeutics named Yue Xiong, Max Kirkby, Claire Weston to its board, effective Aug. 1, 2026.
• Xiong, chief scientific officer since May 2026, previously served as Cullgen’s CSO and a Cullgen director before its merger with Gyre.
• Kirkby, co-owner of Huang and Kirkby Pharma Consulting, previously held senior R&D leadership roles at Bristol-Myers Squibb, Amgen, AstraZeneca.
• Weston, founder and CEO of Tactus AI, previously led Reveal Biosciences until its acquisition by CellCarta, where she later served as a board observer.
• Kirkby joins the compensation committee; Weston joins the audit committee; the appointments expand the board’s clinical, scientific, cross-border operating expertise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161605PRIMZONEFULLFEED9763539) on July 16, 2026, and is solely responsible for the information contained therein.